2020 ASCO Virtual Direct™ Highlights

 

GI
08:05

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on HER2+ mCRC: Is Promising Trastuzumab Deruxtecan Active in Disease Refractory to Standard Therapies?

FEATURING Shikha Jain
  • 136 views
  • July 16, 2020
  • 1
06:45

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on BRAF V600E Mutant mCRC: Does FDA Approved Encorafenib + Cetuximab Significantly Improve OS, ORR, PFS relative vs. SOC?

FEATURING Shikha Jain
  • 379 views
  • July 14, 2020
  • 1
08:01

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on Stage III CRC: Is There a Difference in 5 yr OS Between 3 vs. 6 Months of Adjuvant Therapy?

FEATURING Shikha Jain
  • 1,204 views
  • July 14, 2020
  • 4
06:48

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on CRC: Can We Consider Pembrolizumab a New First Line SoC in Patients With MSI-H mCRC?

FEATURING Shikha Jain
  • 559 views
  • July 14, 2020
  • 5
19:45

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Pancreatic Cancer Highlights: Is Perioperative mFOLFIRINOX More Beneficial Than Gem/nab-P in Resectable Disease? Should Neoadjuvant Therapy Be Considered for Borderline Resectable Disease?

FEATURING Heloisa Soares
  • 828 views
  • July 14, 2020
  • 5
11:51

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on Esophageal / Gastric Cancers: Did Trastuzumab + Trimodality Treatment Increase DFS, PCR or OS of Esophageal Cancer? Is Pertuzumab / Trastuzumab + FLOT Showing Promising pCR?

FEATURING Heloisa Soares
  • 449 views
  • July 14, 2020
  • 3
05:29

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on HCC: Donafenib vs. Sorafenib - Which Combination Is Beneficial as First-line Therapy in Advanced Disease?

FEATURING Heloisa Soares
  • 46 views
  • July 14, 2020